Welcome to the researcher noticeboard. Here you can find information on the latest MND-related news, grant deadlines, awards and meetings. To receive updates on current grants, awards and events relating to MND straight into your inbox, you can subscribe to our quarterly e-newsletter 'The Researcher'.
See below for information on MND Association grant deadlines and other grants available to MND/ALS researchers.
The Spastic Paraplegia Foundation will be awarding research grants in 2019 concerning the causes of, therapies and cures for Primary Lateral Sclerosis (PLS) and Hereditary Spastic Paraplegia (HSP).
Individual grants up to $75,000 per year will be awarded for one and two-year proposals. (Maximum $150,000 for two years.) Proposals on any aspect of Hereditary Spastic Paraplegia (HSP) or Primary Lateral Sclerosis (PLS) (or both) will be considered.
Deadline: 27 September 2019
The Frick Foundation is looking for talented early-career scientists who have already produced excellent supervised work, and are in the early phase of their career as independent principal investigators. Two researchers will receive 100,000 Swiss francs each that can be used over 2 years.
Qualifications: up to 5 years of experience since completion of PhD, scientific track record showing great promise, and excellent research proposal.
Research must be conducted in a public or private research organisation (known as a Host Institution/HI).
Deadline: 30 September 2019
The ALS Association Managing ALS Research Program is intended to improve the lives of people with ALS, and their families and caregivers. This applied research will advance our understanding and the quality of ALS management in the United States, including assistive technology, quality and affordability of services and treatments, and documenting and alleviating the burdens of ALS.
The Association seeks applications that advance our understanding and the quality of ALS management. Academic institutions, technology companies, and commercial entities are encouraged to apply.
- The maximum period of performance is two years.
- The maximum budget for the entire period of performance is $100,000 per year ($200,000 total).
Deadline: 7 October 2019
There is an urgent need for new and improved therapies for ALS, as there is still no cure. The aim of the Lawrence and Isabel Barnett Drug Development Program is to develop new treatments for ALS. This program builds on the Association’s funding of basic and translational research. The Association seeks applications for the preclinical assessment of pre-investigational new drug (pre-IND) therapeutics for ALS that have a high probability of reaching the clinic within three years. The proposed studies are expected to be product-driven and focused on therapeutics.
Academic institutions, biotechnology and pharmaceutical companies are encouraged to apply.
- The maximum period of performance is two years.
- The maximum budget for the entire period of performance is $250,000 per year (500,000 total).
This Funding Opportunity Announcement invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
Applications are now invited. See ‘More information’ for letter of intent and application deadlines.
Meetings and awards
See below for information on events that might be relevant to you.
Location: Tel Aviv, Israel
In recent years we have witnessed major breakthroughs in stem cell biology and regenerative medicine. In particular, stem cells are now being used to model human disease in a petri dish in addition to their abilities in cell therapies and tissue engineering. Some stem cell therapies are being evaluated in clinical trials and also molecules involved in stem cell function are being interrogated for their abilities to activate endogenous tissue repair mechanisms. These basic and translational advancements in the stem cell field along with other key topics will be covered during the Meeting and will be discussed in depth with the participation of speakers of high repute as well as attendees. We have already obtained the consent of several international world leaders in stem cell research to share their recent findings with us.
Location: Birmingham, UK
The European Neuro Convention is Europe’s only trade show for brain and spine experts. The event provides the most up-to date research, data and developments that will enable better patient outcomes, efficiency and cost effectiveness within neurology.
The event provides a unique platform for 3,500 neurologists, therapists, physiotherapists, and commissioning groups to discover the latest innovations currently revolutionising the industry, and hear expert guidance through inspiring CPD accredited seminars, transforming diagnostics, monitoring, rehabilitation, mental health, and brain stimulation.